General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Items 101–200 of 612
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings
Germovsek, E., Cheng, M., & Giragossian, C. (2021) · mAbs · doi:10.1080/19420862.2021.1964935 · Cited by 62
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)
Patel, J., Bass, D., Beishuizen, A., Bocca Ruiz, X., Boughanmi, H., Cahn, A., Colombo, H., Criner, G. J., Davy, K., de-Miguel-Díez, J., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.01870-2021 · Cited by 59
Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
Krippendorff, B., Kuester, K., Kloft, C., & Huisinga, W. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9120-1 · Cited by 59
Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids
Ayyar, V. S., & Jusko, W. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018101 · Cited by 62
Self-citationGibiansky, L. V., & Gibiansky, E. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9125-9 · Cited by 58
Bensalem, A., & Ternant, D. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00874-2 · Cited by 62
Target-mediated drug disposition model and its approximations for antibody–drug conjugates
Gibiansky, L. V., & Gibiansky, E. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9344-y · Cited by 57
Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition
Singh, A. P., Krzyżański, W., Martin, S. W., Weber, G. L., Betts, A. M., Ahmad, A. M., Abraham, A. K., Zutshi, A., Lin, J., & Singh, P. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9690-8 · Cited by 58
Struemper, H., Chen, C., & Cai, W. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.104 · Cited by 57
A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics
Chen, X., Hickling, T. P., Kraynov, E. A., Kuang, B., Parng, C., & Vicini, P. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9517-z · Cited by 60
Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics
Shah, D. K. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9447-8 · Cited by 58
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Louedec, F. L., Leenhardt, F., Marin, C., Chatelut, É., Evrard, A., & Ciccolini, J. (2020) · Vaccines · doi:10.3390/vaccines8040632 · Cited by 62
Krzyżański, W., Wiczling, P., Lowe, P. J., Pigeolet, E., Fink, M., Berghout, A., & Balser, S. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010376966 · Cited by 54
Developability considerations for bispecific and multispecific antibodies
Amash, A., Volkers, G., Farber, P. J., Griffin, D., Davison, K. S., Goodman, A., Tonikian, R., Yamniuk, A. P., Barnhart, B. C., & Jacobs, T. M. (2024) · mAbs · doi:10.1080/19420862.2024.2394229 · Cited by 59
Microdosing: A Critical Assessment of Human Data
Rowland, M. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23290 · Cited by 54
Quantitative systems toxicology
Bloomingdale, P., Housand, C., Apgar, J. F., Millard, B. L., Mager, D. E., Burke, J. M., & Shah, D. K. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.07.003 · Cited by 57
Self-citationKagan, L., Abraham, A. K., Harrold, J. M., & Mager, D. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0098-6 · Cited by 50
Self-citationGrimm, H. P. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9129-5 · Cited by 53
PK–PD Modeling of Protein Drugs: Implications in Assay Development
Roskos, L. K., Schneider, A. K., Vainshtein, I., Schwickart, M., Lee, R., Lu, H. L., Faggioni, R., & Liang, M. (2011) · Bioanalysis · doi:10.4155/bio.11.28 · Cited by 50
Reid, J. L., Zamuner, S., Edwards, K., Rumley, S., Nevin, K., Feeney, M. B., Zecchin, C., Fernando, D., & Wisniacki, N. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13669 · Cited by 50
Lodise, T. P., Wart, S. V., Sund, Z. M., Bressler, A. M., Khan, A., Makley, A. T., Hamad, Y., Salata, R. A., Silveira, F. P., Sims, M. D., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01809-20 · Cited by 50
Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects
Olsson, P., Jacqmin, P., & Ruixo, J. J. P. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746020-00004 · Cited by 49
Review on modeling anti-antibody responses to monoclonal antibodies
Gómez‐Mantilla, J. D., Trocóniz, I. F., Parra-Guillen, Z. P., & Garrido, M. J. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9367-z · Cited by 49
Target-mediated drug disposition model for drugs that bind to more than one target
Gibiansky, L. V., & Gibiansky, E. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9163-3 · Cited by 49
Aston, P. J., Derks, G., Raji, A., Agoram, B. M., & van der Graaf, P. H. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.04.030 · Cited by 49
Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
Malik, P. R. V., Phipps, C. J., Edginton, A. N., & Blay, J. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2259-3 · Cited by 52
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
Ternant, D., Azzopardi, N., Raoul, W., Bejan‐Angoulvant, T., & Paintaud, G. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0680-3 · Cited by 51
Vanhoutte, F. P., Liang, S., Ruddy, M. K., Zhao, A., Drewery, T., Wang, Y., DelGizzi, R., Forleo‐Neto, E., Rajadhyaksha, M., Herman, G. A., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1638 · Cited by 49
Dynamics of target-mediated drug disposition
Peletier, L. A., & Gabrielsson, J. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.09.007 · Cited by 49
Mager, D. E., Mascelli, M. A., Kleiman, N. S., Fitzgerald, D. J., & Abernethy, D. R. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057299 · Cited by 49
Self-citationGadkar, K., Budha, N., Baruch, A., Davis, J. D., Fielder, P., & Ramanujan, S. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.47 · Cited by 48
Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview
An, G. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.804 · Cited by 47
Pan, X., Stader, F., Abduljalil, K., Gill, K. L., Johnson, T. N., Gardner, I. B., & Jamei, M. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00460-1 · Cited by 47
Gibiansky, L. V., & Frey, N. (2011) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9227-z · Cited by 50
Fronton, L., Pilari, S., & Huisinga, W. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9349-1 · Cited by 48
Wang, W., Wang, X., Doddareddy, R., Fink, D., McIntosh, T. S., Davis, H. M., & Zhou, H. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9545-8 · Cited by 47
Sadekar, S., Figueroa, I., & Tabrizi, M. A. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9766-0 · Cited by 47
Gu, J.-M., Zhao, X.-Y., Schwarz, T., Schuhmacher, J., Baumann, A., Ho, E., Subramanyan, B., Tran, K., Myles, T., Patel, C., et al. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0086-4 · Cited by 45
Pharmacokinetic model of target-mediated disposition of thrombopoietin
Jin, F., & Krzyżański, W. (2004) · AAPS PharmSci · doi:10.1208/ps060109 · Cited by 45
Effect of saturable binding on the pharmacokinetics of drugs: a simulation
Øie, S., Guentert, T. W., & Tozer, T. N. (1980) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1980.tb12971.x · Cited by 45
Parameter Identifiability of Fundamental Pharmacodynamic Models
Janzén, D. L. I., Bergenholm, L., Jirstrand, M., Parkinson, J., Yates, J., Evans, N. D., & Chappell, M. J. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00590 · Cited by 44
“Another example is the target-mediated drug disposition model (Mager and Jusko, 2001) applicable to the modeling of biologics, which has been shown to be structurally identifiable (Eudy et al.”
Agersø, H., Overgaard, R. V., Petersen, M. B., Hansen, L., Hermit, M. B., Sørensen, M. H., Petersen, L. C., & Hilden, I. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.009 · Cited by 44
Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 45
Prediction of Exposure–Response Relationships to Support First-in-Human Study Design
Gibbs, J. P. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9236-7 · Cited by 44
Buil‐Bruna, N., López-Picazo, J. M., Martín‐Algarra, S., & Trocóniz, I. F. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0322 · Cited by 46
Recent advances in pharmacokinetic modeling
Ahmad, A. M. (2007) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.540 · Cited by 43
Gibbs, J. P., Doshi, S., Kuchimanchi, M., Grover, A., Emery, M. G., Dodds, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Blom, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.840 · Cited by 42
Assessments of antibody biodistribution
Glassman, P. M., Abuqayyas, L., & Balthasar, J. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.365 · Cited by 42
Low-dimensional neural ODEs and their application in pharmacokinetics
Bräm, D. S., Nahum, U., Schropp, J., Pfister, M., & Koch, G. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09886-4 · Cited by 52
Ma, P. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0615-2 · Cited by 46
Incorporating Target Shedding Into a Minimal PBPK–TMDD Model for Monoclonal Antibodies
Li, L., Gardner, I., Rose, R. H., & Jamei, M. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.73 · Cited by 42
Gibiansky, L. V., Gibiansky, E., & Bauer, R. J. (2011) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9228-y · Cited by 43
Yao, X., Ren, Y., Zhao, Q., Chen, X., Jiang, J., Liu, D., & Hu, P. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105704 · Cited by 41
Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans
Gao, W., & Jusko, W. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042291 · Cited by 48
Self-citationChen, P., Vu, T. C., Narayanan, A., Sohn, W. Y., Wang, J., Boedigheimer, M. J., Welcher, A. A., Sullivan, B., Martin, D. A., Ruixo, J. J. P., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1492-2 · Cited by 41
Population pharmacokinetics of exenatide
Cirincione, B. B., & Mager, D. E. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13135 · Cited by 41
Self-citationWang, B., Li, Y., Yao, Z., & Roskos, L. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12160 · Cited by 43
Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats
Gao, W., & Jusko, W. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175752 · Cited by 45
Self-citationEdlund, H., Melin, J., Parra-Guillen, Z. P., & Kloft, C. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0208-4 · Cited by 43
Garner, R. C. (2010) · Bioanalysis · doi:10.4155/bio.10.6 · Cited by 40
Conner, K. P., Devanaboyina, S. C., Thomas, V. A., & Rock, D. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107574 · Cited by 41
Zheng, S., McIntosh, T. S., & Wang, W. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.357 · Cited by 41
Pharmacokinetic/Pharmacodynamic Modeling in Inflammation
Lon, H., Liu, D., & Jusko, W. J. (2012) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v40.i4.50 · Cited by 40
Self-citationRuixo, J. J. P., Krzyżański, W., Bouman‐Thio, E., Miller, B. H., Jang, H., Bai, S. A., Zhou, H., Yohrling, J., Cohen, A. F., Burggraaf, J., et al. (2009) · Clinical Pharmacokinetics · doi:10.2165/11317190-000000000-00000 · Cited by 40
Wang, Y., Sloey, B., Wong, T., Khandelwal, P., Melara, R., & Sun, Y. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0420-y · Cited by 40
Towards Quantitative Systems Pharmacology Models of Chemotherapy‐Induced Neutropenia
Craig, M. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12191 · Cited by 39
Bloomingdale, P., Bakshi, S., Maaß, C., van Maanen, E., Pichardo‐Almarza, C., Yadav, D. B., van der Graaf, P. H., & Mehrotra, N. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09776-7 · Cited by 42
Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics
Chen, T., Mager, D. E., & Kagan, L. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0917-z · Cited by 38
Self-citationJäger, E., van der Velden, V. H. J., Marvelde, J. G. T., Walter, R. B., Agur, Z., & Vainstein, V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024265 · Cited by 38
Drug Transporters in Xenobiotic Disposition and Pharmacokinetic Prediction
Mao, Q., Lai, Y., & Wang, J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.081356 · Cited by 38
Importance of target-mediated drug disposition for small molecules
Smith, D. A., van Waterschoot, R. A. B., Parrott, N. J., Olivares‐Morales, A., Lavé, T., & Rowland, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.010 · Cited by 40
Admiraal, R., der Zijde, C. M. J., Silva, J., Knibbe, C. A. J., Lankester, A. C., Boelens, J. J., Hale, G., Etuk, A., Wilson, M., Adams, S. P., et al. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00782-0 · Cited by 40
Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology
Li, T. R., Chatterjee, M. S., Lala, M., Abraham, A. K., Freshwater, T., Jain, L., Sinha, V. P., de Alwis, D. P., & Mayawala, K. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2170 · Cited by 39
Yan, X., Lowe, P. J., Fink, M., Berghout, A., Balser, S., & Krzyżański, W. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011421911 · Cited by 38
Wiczling, P., Rosenzweig, M., Vaickus, L., & Jusko, W. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009349376 · Cited by 40
Self-citationPhysiological Considerations for Modeling in vivo Antibody-Target Interactions
Dunlap, T. C., & Cao, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856961 · Cited by 38
Lin, T. S., Stock, W., Xu, H., Phelps, M. A., Lucas, M. S., Guster, S. K., Briggs, B. R., Cheney, C. M., Porcu, P., Flinn, I. W., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903186486 · Cited by 37
Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes
Choi, Y. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050417 · Cited by 39
Landersdorfer, C. B., He, Y., & Jusko, W. J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04108.x · Cited by 36
Self-citationChallenges and considerations for development of therapeutic proteins in pediatric patients
Zhang, Y., Wei, X., Bajaj, G., Barrett, J. S., Meibohm, B., Joshi, A., & Gupta, M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.382 · Cited by 36
Bernadou, G., Campone, M., Merlin, J., Gouilleux‐Gruart, V., Bachelot, T., Lokiec, F. M., Rezaï, K., Arnedos, M., Dieras, V. C., Jimenez, M., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12875 · Cited by 36
Samtani, M. N., Ruixo, J. J. P., Brown, K. H., Cerneus, D. P., & Molloy, C. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008329559 · Cited by 36
Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition
Abraham, A. K., Krzyżański, W., & Mager, D. E. (2007) · The AAPS Journal · doi:10.1208/aapsj0902020 · Cited by 36
Self-citationde Witte, W. E. A., Wong, Y. C., Nederpelt, I., Heitman, L. H., Danhof, M., van der Graaf, P. H., Gilissen, R., & de Lange, E. C. M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1100163 · Cited by 35
In vivo potency revisited – Keep the target in sight
Gabrielsson, J., Peletier, L. A., & Hjorth, S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.011 · Cited by 35
Liu, X. I., Dallmann, A., Wang, Y., Green, D. J., Burnham, J. M., Chiang, B., Wu, P., Sheng, M., Lu, K., van den Anker, J. N., et al. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1406 · Cited by 35
Haraya, K., Tsutsui, H., Komori, Y., & Tachibana, T. (2022) · Pharmaceuticals · doi:10.3390/ph15050508 · Cited by 35
Yan, X., Chen, Y., & Krzyżański, W. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9267-z · Cited by 35
Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers
Krzyżański, W., & Wyska, E. (2007) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0225-z · Cited by 35
Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
Tabrizi, M. A., Funelas, C. B., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9220-2 · Cited by 36
Wang, B., Lau, Y. Y., Liang, M., Vainshtein, I., Zusmanovich, M., Lu, H. L., Magrini, F., Sleeman, M. A., & Roskos, L. K. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011412964 · Cited by 35
gPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug development
Hosseini, I., Gajjala, A., Yadav, D. B., Sukumaran, S., Ramanujan, S., Paxson, R., & Gadkar, K. G. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9562-9 · Cited by 35
Ruixo, J. J. P., Ma, P., & Chow, A. T. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9424-8 · Cited by 34
Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep
Segrave, A. M., Mager, D. E., Charman, S. A., Edwards, G. A., & Porter, C. J. H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063289 · Cited by 34
Self-citationBrenner, M. C., Krzyżański, W., Chou, J., Signore, P. E., Fung, C. K., Guzman, D., Li, D., Zhang, W., Olsen, D. R., Nguyen, V.-T. L., et al. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1918-0 · Cited by 33
Prediction of Drug Disposition on the Basis of its Chemical Structure
Stepensky, D. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0042-0 · Cited by 35
Considerations for setting occupational exposure limits for novel pharmaceutical modalities
Graham, J. C., Hillegass, J., & Schulze, G. E. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104813 · Cited by 34
Pharmacokinetics of recombinant bifunctional fusion proteins
Chen, X., Zaro, J. L., & Shen, W. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.673585 · Cited by 34
Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals
Krzyżański, W., Sutjandra, L., Ruixo, J. J. P., Sloey, B., Chow, A. T., & Wang, Y. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0894-2 · Cited by 32
Le, K. N., Gibiansky, L. V., Good, J., Davancaze, T., Campagne, M. V. L., Loyet, K. M., Morimoto, A. M., Jin, J., Damico‐Beyer, L. A., & Hanley, W. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227223 · Cited by 31
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.